Peter K. Schädlich

507 total citations
20 papers, 414 citations indexed

About

Peter K. Schädlich is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Rheumatology. According to data from OpenAlex, Peter K. Schädlich has authored 20 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Cardiology and Cardiovascular Medicine, 6 papers in Economics and Econometrics and 4 papers in Rheumatology. Recurrent topics in Peter K. Schädlich's work include Health Systems, Economic Evaluations, Quality of Life (6 papers), Diabetes Management and Research (4 papers) and Health and Medical Studies (3 papers). Peter K. Schädlich is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (6 papers), Diabetes Management and Research (4 papers) and Health and Medical Studies (3 papers). Peter K. Schädlich collaborates with scholars based in Germany, United Kingdom and France. Peter K. Schädlich's co-authors include Josef Georg Brecht, E Huppertz, Xiaoyu Chen, Flavio Poldrugo, B Rangoonwala, Franz‐Werner Dippel, Martin Pfohl, Chen Chen, Eva Pagano and Massimo Brunetti and has published in prestigious journals such as Journal of Clinical Medicine, PharmacoEconomics and Current Rheumatology Reports.

In The Last Decade

Peter K. Schädlich

20 papers receiving 383 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter K. Schädlich Germany 12 88 85 82 75 69 20 414
Armelle Gentric France 12 82 0.9× 31 0.4× 56 0.7× 24 0.3× 56 0.8× 49 425
Miriam Kimel United States 14 15 0.2× 51 0.6× 55 0.7× 15 0.2× 88 1.3× 32 556
Kathy Lampl United States 14 327 3.7× 14 0.2× 97 1.2× 70 0.9× 266 3.9× 34 742
Louis Jean Vleming Netherlands 10 53 0.6× 25 0.3× 32 0.4× 76 1.0× 8 0.1× 18 491
Yong‐Chen Chen Taiwan 11 17 0.2× 20 0.2× 44 0.5× 83 1.1× 70 1.0× 41 362
Lee L United States 11 79 0.9× 11 0.1× 50 0.6× 79 1.1× 76 1.1× 28 364
Dwayne Conway United Kingdom 14 1.0k 11.6× 22 0.3× 183 2.2× 125 1.7× 23 0.3× 27 1.3k
Ju Hyun Lee South Korea 14 32 0.4× 27 0.3× 77 0.9× 82 1.1× 74 1.1× 23 638
Žaneta Petrulionienė Lithuania 11 294 3.3× 25 0.3× 76 0.9× 132 1.8× 22 0.3× 61 530
L J Walsh United Kingdom 6 12 0.1× 9 0.1× 29 0.4× 58 0.8× 166 2.4× 7 593

Countries citing papers authored by Peter K. Schädlich

Since Specialization
Citations

This map shows the geographic impact of Peter K. Schädlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter K. Schädlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter K. Schädlich more than expected).

Fields of papers citing papers by Peter K. Schädlich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter K. Schädlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter K. Schädlich. The network helps show where Peter K. Schädlich may publish in the future.

Co-authorship network of co-authors of Peter K. Schädlich

This figure shows the co-authorship network connecting the top 25 collaborators of Peter K. Schädlich. A scholar is included among the top collaborators of Peter K. Schädlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter K. Schädlich. Peter K. Schädlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schädlich, Peter K., Judit Symmank, Axel Dost, Collin Jacobs, & Yvonne Wagner. (2024). Oral Health of Children and Adolescents with Diabetes Mellitus. Journal of Clinical Medicine. 13(22). 6742–6742. 1 indexed citations
2.
Schädlich, Peter K., et al.. (2013). Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany. ClinicoEconomics and Outcomes Research. 5. 203–203. 20 indexed citations
3.
Pfohl, Martin, et al.. (2012). Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany. Journal of Medical Economics. 15(sup2). 14–27. 18 indexed citations
4.
Chen, Xiaoyu, et al.. (2012). Association Between Gout and All-Cause as well as Cardiovascular Mortality: A Systematic Review. Current Rheumatology Reports. 14(2). 195–203. 69 indexed citations
5.
Schädlich, Peter K., et al.. (2012). Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany. Journal of Medical Economics. 16(3). 364–371. 7 indexed citations
6.
Dippel, Franz‐Werner, et al.. (2011). Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review. Cost Effectiveness and Resource Allocation. 9(1). 15–15. 10 indexed citations
7.
Schädlich, Peter K., et al.. (2009). Lebensqualität und Behandlungszufriedenheit unter Therapie mit langwirksamen Analoginsulinen. DMW - Deutsche Medizinische Wochenschrift. 134(12). 565–570. 7 indexed citations
8.
Schädlich, Peter K., et al.. (2006). Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients. PharmacoEconomics. 24(6). 571–591. 19 indexed citations
9.
Schädlich, Peter K., et al.. (2006). Gesundheitsökonomische Evaluationen der Basistherapie von rheumatoider Arthritis unter besonderer Berücksichtigung der Biologika. Gesundheitsökonomie & Qualitätsmanagement. 11(5). 292–301. 1 indexed citations
10.
Schädlich, Peter K., H. Zeidler, A. Zink, et al.. (2005). Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany. PharmacoEconomics. 23(4). 377–393. 6 indexed citations
11.
Schädlich, Peter K., H. Zeidler, A. Zink, et al.. (2005). Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany. PharmacoEconomics. 23(4). 395–420. 17 indexed citations
12.
Schädlich, Peter K., Josef Georg Brecht, B Rangoonwala, & E Huppertz. (2004). Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events. PharmacoEconomics. 22(15). 955–973. 17 indexed citations
13.
Schädlich, Peter K., Josef Georg Brecht, Massimo Brunetti, et al.. (2001). Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension. PharmacoEconomics. 19(5). 497–512. 24 indexed citations
14.
Schädlich, Peter K. & Josef Georg Brecht. (2000). Economic Evaluation of Specific Immunotherapy Versus Symptomatic Treatment of Allergic Rhinitis in Germany. PharmacoEconomics. 17(1). 37–52. 67 indexed citations
15.
Brecht, Josef Georg & Peter K. Schädlich. (2000). Burden of illness imposed by osteoporosis in Germany. 1(1). 26–32. 17 indexed citations
16.
Schädlich, Peter K. & Josef Georg Brecht. (1998). The Cost Effectiveness of Acamprosate in the Treatment of Alcoholism in Germany. PharmacoEconomics. 13(6). 719–730. 41 indexed citations
17.
Schädlich, Peter K., et al.. (1998). Economic Evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany. PharmacoEconomics. 13(1). 147–155. 11 indexed citations
18.
Schädlich, Peter K., E Huppertz, & Josef Georg Brecht. (1998). Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction. PharmacoEconomics. 14(6). 653–669. 30 indexed citations
19.
Schädlich, Peter K., et al.. (1997). Wirtschaftlichkeit von Bisoprolol bei Herzinsuffizienz. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 92(8). 499–504. 1 indexed citations
20.
Brecht, Josef Georg, Flavio Poldrugo, & Peter K. Schädlich. (1996). Alcoholism. PharmacoEconomics. 10(5). 484–493. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Armelle Gentric Breakdown of academic impact, for papers by Miriam Kimel Breakdown of academic impact, for papers by Kathy Lampl Breakdown of academic impact, for papers by Louis Jean Vleming Breakdown of academic impact, for papers by Yong‐Chen Chen Breakdown of academic impact, for papers by Lee L Breakdown of academic impact, for papers by Dwayne Conway Breakdown of academic impact, for papers by Ju Hyun Lee Breakdown of academic impact, for papers by Žaneta Petrulionienė Breakdown of academic impact, for papers by L J Walsh
Rankless by CCL
2026